Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The cost-effectiveness of screening for chronic hepatitis B infection in the United States.

Eckman MH, Kaiser TE, Sherman KE.

Clin Infect Dis. 2011 Jun;52(11):1294-306. doi: 10.1093/cid/cir199.

2.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

3.

Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.

Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH.

Gastroenterology. 2010 Feb;138(2):522-30. doi: 10.1053/j.gastro.2009.10.039.

PMID:
19879275
4.

Cost effectiveness of screening immigrants for hepatitis B.

Wong WW, Woo G, Jenny Heathcote E, Krahn M.

Liver Int. 2011 Sep;31(8):1179-90. doi: 10.1111/j.1478-3231.2011.02559.x.

PMID:
21745300
5.

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.

Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM.

Ann Intern Med. 2005 May 17;142(10):821-31.

PMID:
15897532
6.

Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.

Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H.

Value Health. 2015 Sep;18(6):800-9. doi: 10.1016/j.jval.2015.05.007.

7.
8.

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555.

PMID:
23486701
9.

Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load.

Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV.

Obstet Gynecol. 2014 May;123(5):929-37. doi: 10.1097/AOG.0000000000000124.

10.

Cost-effectiveness of screening for chronic hepatitis C infection in the United States.

Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE.

Clin Infect Dis. 2013 May;56(10):1382-93. doi: 10.1093/cid/cit069.

PMID:
23392392
11.

Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.

Hutton DW, Tan D, So SK, Brandeau ML.

Ann Intern Med. 2007 Oct 2;147(7):460-9.

PMID:
17909207
12.

Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors.

Day FL, Karnon J, Rischin D.

J Clin Oncol. 2011 Aug 20;29(24):3270-7. doi: 10.1200/JCO.2011.35.1635.

PMID:
21788556
13.

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.

JAMA. 2003 Jul 9;290(2):228-37.

PMID:
12851278
14.

Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.

Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG.

J Hepatol. 2009 May;50(5):990-8. doi: 10.1016/j.jhep.2008.12.022.

PMID:
19303657
15.

Cost of treating chronic hepatitis B: comparison of current treatment guidelines.

Robotin M, Patton Y, Kansil M, Penman A, George J.

World J Gastroenterol. 2012 Nov 14;18(42):6106-13. doi: 10.3748/wjg.v18.i42.6106.

16.

Cost-benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: is screening essential?

Jazwa A, Coleman MS, Gazmararian J, Wingate LT, Maskery B, Mitchell T, Weinberg M.

Vaccine. 2015 Mar 10;33(11):1393-9. doi: 10.1016/j.vaccine.2015.01.010.

17.

Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.

Goyal A, Murray JM.

Clin Drug Investig. 2016 Aug;36(8):637-48. doi: 10.1007/s40261-016-0409-8.

PMID:
27166628
18.

Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.

Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C.

PLoS One. 2013 Oct 18;8(10):e78548. doi: 10.1371/journal.pone.0078548.

19.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM.

Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378.

PMID:
22056542
20.

Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.

Tu HA, Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LT, Postma MJ.

Clin Ther. 2010 Jan;32(1):133-44. doi: 10.1016/j.clinthera.2010.01.015.

PMID:
20171419

Supplemental Content

Support Center